YukiYoshida

Of Counsel

(T) + 81.3.6744.1634

Connect:

Share

Yuki Yoshida has more than 10 years of experience representing clients in domestic and cross-border M&A, joint ventures, private equity, and other commercial transactions. He represents buyers, sellers, targets, and financial advisors in domestic and cross-border stock and asset acquisitions, divestitures, restructuring, and strategic alliances. Based on his broad knowledge and experience, Yuki provides clients with attractive commercial solutions for complex legal issues.

Yuki has represented clients in a wide variety of industries, including automotive, chemicals, energy, financial services, health care, manufacturing, pharmaceuticals, and technology. His recent experiences include TDK's $1.3 billion acquisition of InvenSense, Inc. as well as Tonen General Sekiyu's business integration with JX Group.

Yuki also advises clients on corporate governance, securities compliance and regulatory matters, as well as antitrust matters. Recently, his practice also has focused on the legal issues relating to blockchain technologies, and he has written various articles relating to this technology.

Yuki is a member of the Japanese Bar Association and the Daini Tokyo Bar Association. He is actively involved in various pro bono activities. In particular, he regularly serves as a court-appointed counsel for indigent defendants.

Experience

  • OMRON Nohgata sells 80 percent stake to AdvantechJones Day advised OMRON Corporation in the sale of an 80 percent interest in OMRON Nohgata to Advantech.
  • Hitachi acquires Mitsubishi Electric's particle therapy system businessJones Day advised Hitachi, Ltd. in its acquisition of the particle therapy system business from Mitsubishi Electric Corporation.
  • Orocobre Limited secures AUD$361 million funding through private placement and underwritten accelerated entitlement offerJones Day represented Orocobre Limited, a leading lithium chemicals producer, in connection with its AUD$361 million capital raising, comprising of a AUD$282 million private placement to Toyota Tsusho Corporation and an underwritten entitlement offer raising AUD$79 million.
  • Cardinal Health acquires leading patient product portfolio from Medtronic for $6.1 billionJones Day advised Cardinal Health on the acquisition of Medtronic's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash.
  • Reynolds American acquired by British American Tobacco Plc in deal valued at $49 billionJones Day advised Reynolds American Inc. ("RAI") regarding the acquisition by British American Tobacco, p.l.c. ("BAT") of 57.8 percent of the outstanding shares of RAI not owned by BAT and its affiliates in a transaction valued at $49 billion.
  • TDK acquires InvenSense for $1.3 billionJones Day advised TDK Corporation in its $1.3 billion acquisition of InvenSense, Inc.
  • TonenGeneral Sekiyu combines with JX GroupJones Day advised TonenGeneral Sekiyu K.K. in connection with the business integration with JX Group, which forms the largest oil refiner in Japan.
  • Sumitomo Dainippon Pharma acquires Tolero Pharmaceuticals, Inc.Jones Day advised Sumitomo Dainippon Pharma Co. Ltd., a leading pharmaceutical company based in Japan, in its acquisition of Tolero Pharmaceuticals, Inc.
  • MAHLE sells its industrial filtration business to Filtration GroupJones Day advised MAHLE in the sale of its industrial filter business to Filtration Group Corporation.
  • International Automotive Components Group North America sells IAC Japan Co., Ltd.Jones Day advised International Automotive Components Group North America, LLC in its sale by International Automotive Components Group (IAC) of IAC Japan Co., Ltd., IAC's domestic Japan manufacturing business, to Akeel Holdings LLC.
  • Newell Rubbermaid issues $8 billion in Senior Notes offeringJones Day represented Newell Rubbermaid Inc., a global marketer of consumer and commercial products, in connection with its public offering of $8 billion aggregate principal amount of Senior Notes.
  • DENKA buys Neoprene polychloroprene business of DuPont™Jones Day advised Denki Kagaku Kogyo Kabushiki Kaisha (DENKA) in the purchase of the Neoprene polychloroprene business of DuPont™ by Denka Performance Elastomer LLC, a joint venture company owned 70 percent by DENKA and 30 percent by Mitsui & Co., Ltd.
  • Valmet acquires Metso's Process Automation Systems business for €340 million (US$369.3 million)Jones Day advised Valmet Corporation in its acquisition of Metso's Process Automation Systems business for €340 million (US$369.3 million).
  • Quintiles and Quest Diagnostics to form joint venture to provide clinical trials laboratory servicesJones Day is advising Quintiles Transnational Holdings Inc. in its joint venture with Quest Diagnostics Inc. to form a global clinical trials laboratory services business.
  • SCHOTT sells 71.6 percent shares in a Japanese listed subsidiary to MV Japan by way of a public takeover bidJones Day advised Schott in its sale of 71.6 percent shares in SCHOTT Moritex Corporation, a company listed on the Tokyo Stock Exchange, to MV Japan Co., Ltd., an SPC owned by an investment fund operated by CITIC Capital Holdings Limited.
  • Sumitomo Bakelite acquires Vaupell Holdings for $269 millionJones Day advised Sumitomo Bakelite Co., Ltd. in the $269 million acquisition of Vaupell Holdings, Inc., a global leader in highly engineered thermoplastic and composite products for the aerospace, defense, medical and commercial markets, from Miami-based private equity fund H.I.G. Capital.
  • Nordson acquires Xaloy Superior Holdings for $200 millionJones Day advised Nordson Corporation, a leader in precision dispensing equipment for applying industrial liquid and powder coatings, adhesives, and sealants to numerous consumer and industrial products during manufacturing operations, in connection with its $200 million acquisition of Xaloy Superior Holdings, Inc., a global manufacturer of melt delivery components for injection and extrusion machinery in the global plastic processing industry.
  • Molycorp acquires rare earth processor Neo Material Technologies in CDN$1.3 billion (US$1.26 billion) transactionJones Day advised Molycorp, Inc. in its CDN$1.3 billion (US$1.26 billion) acquisition of Neo Material Technologies Inc.
  • Dainippon Sumitomo Pharma acquires oncology-focused biotechnology company Boston Biomedical for $200 million plus up to $2.2 billion in earnoutsJones Day advised Dainippon Sumitomo Pharma Co. in its acquisition of Boston Biomedical Inc. ("BBI") for US$200 million plus up to US$2.2 billion in earnouts.
  • Molycorp forms joint venture with Mitsubishi and Daido Steel to manufacture rare earth magnetsJones Day advised Molycorp Minerals LLC with its entry into a Japanese joint venture with Mitsubishi Corporation and Daido Steel.
    • View All

    October 2019 Jones Day Publications

    Japan Legal Update Vol. 49 | September–October 2019

    August 2019 Newsletters

    Japan Legal Update Vol. 48 | July–August 2019

    June 2019 Jones Day Publications

    Japan Legal Update Vol. 47 | May–June 2019

    April 2019 Jones Day Publications

    Japan Legal Update | Vol. 46

    March 2019 Newsletters

    Japan Legal Update | Vol. 45

    February 2019 Jones Day Publications

    Japan Legal Update | Vol. 44, February 2019

    January 2019 Jones Day Publications

    Japan Legal Update Vol. 43 | December 2018/January 2019

    December 2018 Jones Day Publications

    ジョーンズ・デイ・アラート：デラウェア州最高裁判所によるMAE（Materially Adverse Effect）条項に関する画期的な判決

    November 2018 Jones Day Publications

    Japan Legal Update Vol. 42 | November 2018

    October 2018 Jones Day Publications

    Japan Legal Update Vol. 41 | October 2018
    View All
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.